Fundraising Fox

リジェネフロ

Kyoto, JP · 3 known investors

Rege Nephro develops regenerative medicine therapies for kidney disease, focusing on nephron progenitor cell research and differentiation from iPS cells. The company aims to commercialize treatments for patients with kidney disorders and reduce reliance on dialysis and transplantation.

BiotechHealthtechMedical Devices

Investors · 3

Global BrainTokyo · $100K – $184M
Kyoto University Innovation CapitalKyoto
Nippon Venture CapitalTokyo · $1.5M – $269M

Competitors · 1

by search overlap
2022年4月 出資3 shared keywordsPR TIMES is a press release distribution service that helps companies distribute news releases to media and the public, with content syndicated across more than 260 partner sites. It is aimed at businesses seeking media coverage and PR marketing in Japan.

Companies competing with リジェネフロ for the same Google search keywords, organic and paid, via search-intersection analysis.

Frequently asked questions

What does リジェネフロ do?
Rege Nephro develops regenerative medicine therapies for kidney disease, focusing on nephron progenitor cell research and differentiation from iPS cells. The company aims to commercialize treatments for patients with kidney disorders and reduce reliance on dialysis and transplantation.
Who are リジェネフロ's investors?
リジェネフロ's investors include Global Brain, Kyoto University Innovation Capital, Nippon Venture Capital.
Where is リジェネフロ headquartered?
リジェネフロ is headquartered in Kyoto, JP.